These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24006453)

  • 1. Coronary stents: novel developments.
    Stefanini GG; Taniwaki M; Windecker S
    Heart; 2014 Jul; 100(13):1051-61. PubMed ID: 24006453
    [No Abstract]   [Full Text] [Related]  

  • 2. The optimal treatment of STEMI: new pharmacological and device approaches.
    Movahed MR
    Panminerva Med; 2013 Dec; 55(4):339-43. PubMed ID: 24434342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
    Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
    Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A
    Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
    Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
    EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Right coronary artery 'diverticulosis' 4 years after sirolimus-eluting stent implantation associated with very late stent thrombosis.
    Good RI; Kalra S; Lee TC
    Heart; 2013 Nov; 99(21):1627. PubMed ID: 23749781
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioresorbable vascular scaffolds: the shape of things to come?
    Safian RD
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):472-3. PubMed ID: 22431381
    [No Abstract]   [Full Text] [Related]  

  • 10. Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation.
    Orban M; Joner M; Riegger J; Steigerwald K; Tada T; Ibrahim T; Laugwitz KL; Byrne RA; Kastrati A; Massberg S
    EuroIntervention; 2013 Jul; 9(3):412-3. PubMed ID: 23034199
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
    Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
    Hannan EL; Zhong Y; Wu C; Walford G; Holmes DR; Jacobs AK; Stamato NJ; Venditti FJ; Sharma S; Fergus I; King SB
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1097-105. PubMed ID: 22707353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-year clinical outcomes of first-generation drug-eluting stents: a propensity-matched analysis.
    Tarantini G; Barioli A; Facchin M; Frigo AC; Napodano M; Buja P; D'Amico G; Iliceto S; Isabella G
    Coron Artery Dis; 2013 Aug; 24(5):440-8. PubMed ID: 23695366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus-eluting bioabsorbable stent--Abbot Vascular programme.
    Onuma Y; Piazza N; Ormiston JA; Serruys PW
    EuroIntervention; 2009 Dec; 5 Suppl F():F98-F102. PubMed ID: 22100687
    [No Abstract]   [Full Text] [Related]  

  • 17. Innovations in drug-eluting stents.
    Nallu K; Yang DC; Swaminathan RV; Kim LK; Feldman D
    Panminerva Med; 2013 Dec; 55(4):345-52. PubMed ID: 24434343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry).
    Dvir D; Barbash IM; Torguson R; Badr S; Sardi GL; Laynez-Carnicero A; Ben-Dor I; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2013; 14(3):128-33. PubMed ID: 23642502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial.
    Tandjung K; Basalus MW; Sen H; Stoel MG; van Houwelingen KG; Louwerenburg JH; de Man FH; Linssen GC; Saïd SA; Kleijne MA; van der Palen J; von Birgelen C
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):396-405. PubMed ID: 23359390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.